Evidence map›Paper›PMID 34719731›Full record

Trial reportPsychopharmacology2022

Acute effects of Δ

Lisa-Marie Greenwood, Samantha J Broyd, Hendrika H van Hell, Juanita Todd, Alison Jones, Robin M Murray, Rodney J Croft, Patricia T Michie, Nadia Solowij

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. The effects of preventative cannabidiol in a maleFrontiers in cellular neuroscience · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Lisa-Marie Greenwood *Research School of Psychology, Australian National University, Canberra, ACT, Australia. lisa-marie.greenwood@anu.edu.au.ORCID http://orcid.org/0000-0002-0762-1921
Samantha J Broyd *School of Psychology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia.
Hendrika H van HellSchool of Psychology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia.
Juanita ToddSchool of Psychology and Priority Research Centre for Brain and Mental Health, University of Newcastle, Newcastle, NSW, Australia.
Alison JonesFaculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.
Robin M MurrayInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Rodney J CroftSchool of Psychology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia.
Patricia T MichieSchool of Psychology and Priority Research Centre for Brain and Mental Health, University of Newcastle, Newcastle, NSW, Australia.
Nadia SolowijThe Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), New Lambton Heights, NSW, Australia.
University of Wollongong · AUUniversity of Newcastle Australia · AUAustralian National University · AUKing's College London · GB

Funding

National Health and Medical Research Council of Australia NHMRC Project Grant 1007593
6 · The paper itself

Abstract

rationaleMismatch negativity (MMN) is a candidate endophenotype for schizophrenia subserved by N-methyl-D-aspartate receptor (NMDAR) function and there is increasing evidence that prolonged cannabis use adversely affects MMN generation. Few human studies have investigated the acute effects of cannabinoids on brain-based biomarkers of NMDAR function and synaptic plasticity.

objectivesThe current study investigated the acute effects of Δ

methodsIn a randomised, double-blind, crossover placebo-controlled study, 18 frequent and 18 less-frequent cannabis users underwent 5 randomised drug sessions administered via vaporiser: (1) placebo; (2) THC 8 mg; (3) CBD 400 mg; (4) THC 8 mg + CBD 4 mg [THC + CBD

resultsRelative to placebo, both THC and CBD were observed to increase duration and intensity MMN amplitude in less-frequent users, and THC also increased frequency MMN in this group. The addition of low-dose CBD added to THC attenuated the effect of THC on duration and intensity MMN amplitude in less-frequent users. The same pattern of effects was observed following high-dose CBD added to THC on duration and frequency MMN in frequent users.

conclusionsThe pattern of effects following CBD combined with THC on MMN may be subserved by different underlying neurobiological interactions within the endocannabinoid system that vary as a function of prior cannabis exposure. These results highlight the complex interplay between the acute effects of exogenous cannabinoids and NMDAR function. Further research is needed to determine how this process normalises after the acute effects dissipate and following repeated acute exposure.

Indexed as

CannabidiolCannabinoidsCannabisHallucinogensDronabinolHumansCannabidiolCannabinoidsDronabinolHallucinogensBrain electrophysiologyCannabidiol (CBD)CannabisMismatch negativity (MMN)Δ9-Tetrahydrocannabinol (THC)

Identifiers

PMID34719731
OpenAlexW3208686246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.